Transarterial chemoembolization combined with lenvatinib vs transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis

Table 2 Other basic characteristics and quality assessment of included studies

Ref.	Prior HBV infection, TACE + LEN1	Prior HBV infection, TACE + SOR1	ECOG-PS (0-1/2), TACE + LEN	ECOG-PS (0-1/2), TACE + SOR	Child-Pugh (A/B), TACE + LEN	Child-Pugh (A/B), TACE + SOR	Invading blood vessels, TACE + LEN1	Invading blood vessels, TACE + SOR1	Distant metastasis, TACE + LEN1	Distant metastasis, TACE + SOR1	AFP (< 400/≥ 400, ng/mL), TACE + LEN	AFP (< 400/≥ 400, ng/mL), TACE + SOR
Ding et al[15], 2021	30/2	29/3	24/7	22/10	22/10	28/4	32/0	32/0	19/13	23/9	16/16	14/18
Xue et al[16], 2021	46/4	97/3	37/13	84/16	41/9	84/16	36/14	81/19	27/23	45/55	NA	NA
Xu et al[17], 2023	38/5	36/5	20/23	23/18	32/11	28/13	17/26	15/26	11/32	12/29	23/20	26/15
Yang et al[18], 2021	36/2	34/4	27/11	27/11	37/1	37/1					14/24	15/23
Zhang et al[19], 2022	50/3	55/4	43/10	45/14	52/1	57/2	36/17	41/18	36/17	39/20	20/33	25/34
Zhao et al[20], 2022	22/1	21/11	12/11	18/14	19/4	27/5	10/13	18/14	1/22	22/10	NA	NA

¹No/Yes.

TACE: Transarterial chemoembolization; LEN: Lenvatinib; SOR: sorafenib; ECOG: Eastern Cooperative Oncology Group; AFP: Alpha fetoprotein; NA: Not available.